Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

EGFR C797S inhibitor

DRUG CLASS:

EGFR C797S inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	ER121 Sensitive: D – Preclinical ER121 Sensitive : D	ER121 Sensitive: D – Preclinical ER121 Sensitive : D
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	ER121 Sensitive: D – Preclinical ER121 Sensitive : D	ER121 Sensitive: D – Preclinical ER121 Sensitive : D
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR L858R + EGFR C797S	Non Small Cell Lung Cancer	EGFR L858R + EGFR C797S	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR C797S	Non Small Cell Lung Cancer	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D	VRN11 Sensitive: D – Preclinical VRN11 Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	TRX-221 Sensitive: D – Preclinical TRX-221 Sensitive : D	TRX-221 Sensitive: D – Preclinical TRX-221 Sensitive : D